Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Objective The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. Methods Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled. A subgroup analysis involving patients who achieved a response (defined as a weight loss of >/=5% after 12 weeks of treatment) was conducted. The outcomes of the pooled analysis were then used to construct a Markov health economic model covering an 11-y period. The incidences of diabetes-related micro- and macrovascular complications were derived from the United Kingdom Prospective Diabetes Study. The effects of changes in body mass index, and the impact of micro- and macrovascular complications on utilities were derived from published sources. Publicly available cost data were used and are presented here in 2001 Euros. Discounting of 3% was applied. A probabilistic sensitivity analysis was conducted to examine the robustness of results. Results A total of 1249 patients treated with orlistat and 1230 given placebo were eligible for the intent-to-treat analysis. At the end of the study period, 23% of orlistat patients achieved a weight reduction of >/=5%. These patients showed a mean decrease in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2 mmHg. The base-case economic analysis revealed…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The addition of weight-loss medications has been shown to achieve significantly more weight loss than lifestyle interventions alone and produce greater A1C lowering and improvements in cardiometabolic risk factors.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [735]
In the citing paper
“The study’s weight-loss medication arms consistently resulted in: (1) greater weight loss than lifestyle alone, (2) lower A1C values despite less need for DM medications, (3) reductions in BP, (4) lower triglycerides and higher HDL-C, (5) decreased levels of hepatic transaminases, and (6) improvements in inflammatory and other biomarkers such as CRP, fibrinogen, and adiponectin, when compared to”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [735]
In the citing paper
“All FDAdapproved medications for chronic weight management have also been demonstrated to be effective and safe in both RCTs and a meta-analysis involving persons with T2D.735–742”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [735]
In the citing paper
“and has been shown to be effective in those with T2D.735–737,739”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [735]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L., & Diabetologicznego, P. P. T. (2014) · Via Medica Journals · Cited by 1,192
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Mark, D. B., Hlatky, M. A., Califf, R. M., Naylor, C. D., Lee, K. L., Armstrong, P. W., Barbash, G., White, H., Simoons, M. L., Nelson, C. L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322106 · Cited by 521
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Research works printed but not linked: 1
- Groscurth A, Vetter W, Suter PM . Is the Swiss population gaining body weight? Body mass index insurance applications between 1950 and 1990. Schweiz Rundsch Med Prax 2003; 92: 2191–2200.
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Meta‐ and cost‐effectiveness analysis of commercial weight loss strategies
Finkelstein, E. A., & Kruger, E. (2014) · Obesity · doi:10.1002/oby.20824 · Cited by 147
“The Orlistat studies report ACERs ranging between US $23,290 and US $102,000 per QALY [converted to USD (62)] (63-76).”
BackgroundBehavior therapy for obesity: where are we now?
Sarwer, D. B., von Sydow Green, A., Vetter, M. L., & Wadden, T. A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832f5a79 · Cited by 120
Anselmino, M., Bammer, T., Cebrián, J. M. F., Daoud, F., Romagnoli, G., & Torres, A. (2009) · Obesity Surgery · doi:10.1007/s11695-009-9946-z · Cited by 117
Orlistat: A Review of its Use in the Management of Obesity
Henness, S., & Perry, C. M. (2006) · Drugs · doi:10.2165/00003495-200666120-00012 · Cited by 135
Orlistat: current status in clinical therapeutics
McClendon, K. S., Riche, D. M., & Uwaifo, G. I. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903321485 · Cited by 93
“There have been several meta-analyses of orlistat’s utility both for weight maintenance and the associated improvement of surrogates and components of the metabolic syndrome [74-86].”
BackgroundCost-effectiveness of pharmacological anti-obesity treatments: a systematic review
Neovius, M., & Narbro, K. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.189 · Cited by 59
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 65
Action on obesity: comprehensive care for all
Wass, J. A. H., & Finer, N. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-1-4 · Cited by 44
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
Granström, O., Bergenheim, K., McEwan, P. C., Sennfält, K., & Henriksson, M. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.09.003 · Cited by 48
Medication use for the treatment of diabetes in obese individuals
Wilding, J. P. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4288-1 · Cited by 49
Galani, C., Schneider, H., & Rutten, F. (2007) · Sozial- und Präventivmedizin · doi:10.1007/s00038-007-7014-9 · Cited by 44
Garvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S. E., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice · doi:10.4158/ep14279.cs · Cited by 45
Incremental cost‐effectiveness of evidence‐based non‐surgical weight loss strategies
Finkelstein, E. A., & Verghese, N. R. (2019) · Clinical Obesity · doi:10.1111/cob.12294 · Cited by 38
“Consistent with the National Institute for Health and Care Excellence guidelines on economic modelling,(45) several studies which assessed Orlistat (the chemical component in Alli and Xenical) estimated that for a 12-month intervention, all weight is regained 4 years after the drug therapy began.(40,46,47) Based on th…”
MethodVasdeki, D., Koufakis, T., Tsamos, G., Busetto, L., Zebekakis, P. E., & Kotsa, K. (2022) · Nutrients · doi:10.3390/nu14224801 · Cited by 33
Golay, A., Brock, E., Gabriel, R., Konrad, T., Lalic, N. M., Laville, M., Mingrone, G., Petrie, J. R., Phan, T., Pietiläinen, K. H., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12114 · Cited by 34
Self-citationCost-Effectiveness of Pharmacotherapy to Reduce Obesity
Veerman, L. J., Barendregt, J. J., Forster, M., & Vos, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026051 · Cited by 36
“A number of previous studies [42,43,44,45,46] use a utility value of 0.”
Obesity Management Interventions: A Review of the Evidence
Yaskin, J. C., Toner, R. W., & Goldfarb, N. I. (2009) · Population Health Management · doi:10.1089/pop.2008.0049 · Cited by 32
Xue, Y., Zou, H., Ruan, Z., Chen, X., Lai, Y., Yao, D., Ung, C. O. L., & Hu, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1254398 · Cited by 28
“Cohort-based Markov model was commonly applied to conceptualize a series of health states in relation to obesity and transitions between the states in most of the studies (51 – 53, 61 – 64, 67, 68, 70, 71).”
BackgroundMethodPharmacotherapy for obesity in individuals with type 2 diabetes
Chukir, T., Shukla, A. P., Saunders, K. H., & Aronne, L. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428558 · Cited by 22
Economic evaluation of treatment with orlistat in Italian obese patients
Iannazzo, S., Zaniolo, O., & Pradelli, L. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253591 · Cited by 23
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Saleem, M., Fareed, M. M., Saani, M. S. A., & Shityakov, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222837 · Cited by 20
“Type 2 diabetes mellitus is predicted to affect 552 million individuals globally by 2030 (Colosia et al., 2013; Ruof et al., 2005).”
BackgroundKondo, M., Hoshi, S.-L., & Toi, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604869 · Cited by 13
“Total hysterectomy, etc (DPC 1200203x01x0xx+ reimbursements by FFS) 1183 839 Change by±50% Matsuda and Ishikawa (2003)”
BackgroundInfluentialL'efficacité médico-économique de l'éducation thérapeutique chez des patients obèses
Sanguignol, F., Lagger, G., & Golay, A. (2009) · Education thérapeutique du patient - Therapeutic patient education · doi:10.1051/tpe/2009011 · Cited by 15
“Selon le modèle de Markov, une perte de poids de 8 kg maintenue pendant 10 ans chez des patients obèses diabétiques permet d’économiser 13000 e par patient et par année [13].”
BackgroundSelf-citationGreen, L. E., Dinh, T., Hinds, D. A., Walser, B. L., & Allman, R. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0089-6 · Cited by 11
Economic Evaluations of Anti-obesity Interventions in Obese Adults: An Umbrella Review
Sharif, F. V., Yousefi, N., & Sharif, Z. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07104-9 · Cited by 10
Golay, A. (2006) · KARGER eBooks · doi:10.1159/000094430 · Cited by 8
Self-citationEmerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines
Correia, M., & Haynes, W. G. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.643 · Cited by 7
“In addition, there is some evidence that orlistat treatment might be cost-effective, particularly in obese diabetics that respond favourably to the prescription [14].”
BackgroundTratamiento de la diabetes tipo 2: revisión de las opciones y prioridades terapéuticas actuales
Arroyo, J., Caixàs, A., & Pi‐Sunyer, F. X. (2007) · Medicina Clínica · doi:10.1157/13113289 · Cited by 3
Pharmakotherapie der Adipositas
Hamann, A. (2007) · Der Internist · doi:10.1007/s00108-007-1981-z · Cited by 2
OBESITY IN TYPE 2 DIABETES: A REVIEW OF HEALTH ECONOMICS EVIDENCES
Kiadaliri, A., & Najafi, B. (2012) · Cited by 1
Nutzen und Risiko der medikamentösen Adipositastherapie
Hamann, A., & Tafel, J. (2008) · Der Diabetologe · doi:10.1007/s11428-008-0224-9
Adeyemi, A. (2014) · Texas ScholarWorks (Texas Digital Library)
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Lane, W. S., Raskin, P., Tamborlane, W. V., & Rothermel, C. (2014)
Nutzen und Risiko der medikamentösen Adipositastherapie
Heidelberg, U. (2008)
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000235329.84906.3b
Finer, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch18
Orlistat and Sibutramine in the Management of Obesity
Wyatt, H. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_15 · Cited by 1
“A meta-analysis of seven randomized control trials of orlistat in overweight and obese patients with type 2 diabetes found 23% of orlistat patients achieved a weight reduction ≥ 5% [79].”
BackgroundMethodInfluential
Metadata
- Authors
- Ruof, J., Golay, A., Berne, C., Collin, C., Lentz, J., & Maetzel, A.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- University Hospital of Geneva (CH)
- Uppsala University Hospital (SE)
- Roche (Sweden) (SE)
- University Health Network (CA)
- Corresponding author
- Ruof, J
- Venue
- International Journal of Obesity
- Published
- 2005-03-01
- Volume
- 29
- Issue
- 5
- Pages
- 517-523
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W1982184733
- Cited by
- 40
- References
- 30
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 5 · 2013: 2 · 2012: 1
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- orlistat, type 2 diabetes, obesity, weight loss, cost-effectiveness, drug reimbursement, quality-adjusted life years, HbA1c, microvascular complications, macrovascular complications, Sweden, Switzerland
- MeSH terms
- Orlistat, Blood Pressure, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Insurance, Health, Reimbursement, Lactones, Obesity, Sweden, Switzerland, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.